Essentia Biosciences completes nearly RMB 100 million Pre-A round financing

Recently, Essentia Biosciences completed a nearly 100 million Pre-A round of financing. This round was jointly led by Haier Venture Capital and Fuzhi Investment, with participation from Yuanbio Venture Capital, Zero2IPO Venture, He Ding Gong Investment, and Moltek.

Since its establishment in 2022, Essentia Biosciences has rapidly completed two rounds of angel financing, efficiently advancing the technical roadmap and process validation for its lead pipeline, ESN5800 (pluripotent stem cell-derived islet cells). Its core technical indicators have reached internationally top-tier levels, and animal studies have demonstrated excellent efficacy in regulating blood glucose and reversing diabetes. In 2025, a GMP-standard R&D and production laboratory located in the Daxing Airport Comprehensive Bonded Zone became operational, marking Essentia Biosciences as Beijing's first drug development enterprise to conduct bonded R&D.

In the field of diabetes treatment using pluripotent stem cell-directed differentiation into islet cells, one of the most promising and highly anticipated directions in stem cell therapy in recent years, this round of financing will provide industrial empowerment for Essentia Biosciences. It will support the steady advancement of non-clinical studies for the ESN5800 pipeline, deepen efforts to enhance product cost competitiveness, and accelerate clinical trial applications and the development of subsequent iterative pipelines.